What's Needed to Better Pulmonary Fibrosis Research


A look at how the rare pulmonary disease field of research has been limited.

Mean pulmonary fibrosis (PF) patient age is approximately 60 years old; disease progression and pathophysiology is diverse; and, as discussed earlier in an interview with HCPLive, signs and symptoms are not well-interpreted by at-risk patients.

These factors and more could hinder the rate and makeup of clinical trials assessing promising therapies for the rate pulmonary disease. So what can be done to address the issue?

In the next segment of a continued discussion with HCPLive, Greg Cosgrove, MD, chief medical officer of the Pulmonary Fibrosis Foundation, discussed the necessary teamwork—from patients to physicians to organizations like his own—in bettering available research.

He also explained the value of patient participation in registry databases, like that used by the foundation.

“As I tell my patients, none of the efforts we have—the advantages and successes in the research space could happen without them participating,” he said.

Unfortunately, sometimes it’s another hurdle for patient at odds to clear.

Related Videos
Video 2 - "Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment "
Video 1 - "Novel Cardio Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause "
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Heart Failure Treatment Outcomes and Contraindications
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
© 2024 MJH Life Sciences

All rights reserved.